Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 48
- Registration Number
- NCT04963283
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States
🇺🇸UCHealth Harmony Campus, Fort Collins, Colorado, United States
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
- Conditions
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Jennifer King
- Target Recruit Count
- 50
- Registration Number
- NCT04876456
- Locations
- 🇺🇸
Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 12
- Registration Number
- NCT04868773
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 388
- Registration Number
- NCT04804813
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- University of Leipzig
- Target Recruit Count
- 40
- Registration Number
- NCT04767906
- Locations
- 🇩🇪
Charite Universitätsmedizin, Campus Virchow Klinikum, Klinik für Hepatologie/Gastroenterologie, Berlin, Germany
🇩🇪Technische Universität Dresden, Medizinische Fakultät Carl Gustav Carus Medizinische Klinik und Poliklinik I, Dresden, Saxonia, Germany
🇩🇪University Hospital Leipzig, Leipzig, Saxonia, Germany
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT04760288
- Locations
- 🇪🇸
Hospital Universitario Virgen del Rocio, Sevilla, Spain
Cabozantinib With Topotecan-Cyclophosphamide
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT04661852
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 1540
- Registration Number
- NCT04637204
- Locations
- 🇬🇧
Ipsen Facility, Slough, United Kingdom
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 30
- Registration Number
- NCT04631744
- Locations
- 🇺🇸
New Jersey Urology/Summit Medical Group, Saddle Brook, New Jersey, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
Cabozantinib in Hepatocellular Carcinoma
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Stephen Chan Lam
- Target Recruit Count
- 20
- Registration Number
- NCT04588051
- Locations
- 🇰🇷
ASAN Medical Center, Seoul, Korea, Republic of
🇭🇰Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.